{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ACRV/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T02:34:35.325Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11349,"canonical_name":"Acrivon Therapeutics, Inc.","cik":"0001781174","uei":null,"lei":null,"duns":null,"ticker":"ACRV"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":64},"count":64,"timeline":[{"ts":"2026-10-07","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-10-07","url_slug":"/sec/cik-0001781174/4/0000905148-26-004399","accession_number":"0000905148-26-004399","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"3","title":"3 — Acrivon Therapeutics, Inc. — 2026-09-02","url_slug":"/sec/cik-0001781174/3/0000905148-26-004064","accession_number":"0000905148-26-004064","importance":30},{"ts":"2026-09-02","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-09-02","url_slug":"/sec/cik-0001781174/4/0000905148-26-004065","accession_number":"0000905148-26-004065","importance":30},{"ts":"2026-08-27","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-27","url_slug":"/sec/cik-0001781174/4/0000905148-26-003968","accession_number":"0000905148-26-003968","importance":30},{"ts":"2026-08-25","kind":"sec.filing","form_type":"144","title":"144 — Acrivon Therapeutics, Inc. — 2026-08-25","url_slug":"/sec/cik-0001781174/144/0000905148-26-003924","accession_number":"0000905148-26-003924","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-003836","accession_number":"0000905148-26-003836","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-003837","accession_number":"0000905148-26-003837","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-003838","accession_number":"0000905148-26-003838","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-003839","accession_number":"0000905148-26-003839","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-003840","accession_number":"0000905148-26-003840","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Acrivon Therapeutics, Inc. — 2026-08-13","url_slug":"/sec/cik-0001781174/schedule-13g-a/0001875620-26-000015","accession_number":"0001875620-26-000015","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Acrivon Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001781174/10-q/0001193125-26-346819","accession_number":"0001193125-26-346819","importance":45},{"ts":"2026-08-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Acrivon Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001781174/8-k/0001193125-26-346859","accession_number":"0001193125-26-346859","importance":35},{"ts":"2026-08-12","kind":"sec.filing","form_type":"S-8","title":"S-8 — Acrivon Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001781174/s-8/0001193125-26-347003","accession_number":"0001193125-26-347003","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001781174/4/0000905148-26-003499","accession_number":"0000905148-26-003499","importance":30},{"ts":"2026-07-23","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-07-23","url_slug":"/sec/cik-0001781174/4/0000905148-26-003334","accession_number":"0000905148-26-003334","importance":30},{"ts":"2026-07-21","kind":"sec.insider.s","reporter":"Miller Mary","title":"Chief Legal Officer","shares":573,"price_per_share":1.76,"usd_value":1008,"security_title":"Common Stock","importance":35.00100848},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001781174/4/0000905148-26-003033","accession_number":"0000905148-26-003033","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001781174/4/0000905148-26-003035","accession_number":"0000905148-26-003035","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"8-K","title":"8-K — Acrivon Therapeutics, Inc. — 2026-06-17","url_slug":"/sec/cik-0001781174/8-k/0001193125-26-274410","accession_number":"0001193125-26-274410","importance":35},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002549","accession_number":"0000905148-26-002549","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002550","accession_number":"0000905148-26-002550","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002551","accession_number":"0000905148-26-002551","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002552","accession_number":"0000905148-26-002552","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002553","accession_number":"0000905148-26-002553","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002556","accession_number":"0000905148-26-002556","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002558","accession_number":"0000905148-26-002558","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001781174/4/0000905148-26-002560","accession_number":"0000905148-26-002560","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001781174/4/0000905148-26-002498","accession_number":"0000905148-26-002498","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001781174/4/0000905148-26-002499","accession_number":"0000905148-26-002499","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001781174/4/0000905148-26-002500","accession_number":"0000905148-26-002500","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001781174/4/0000905148-26-002501","accession_number":"0000905148-26-002501","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Acrivon Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001781174/4/0000905148-26-002502","accession_number":"0000905148-26-002502","importance":30},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Magovcevic-Liebisch Ivana","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"RA CAPITAL MANAGEMENT, L.P.","title":"","shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"RA Capital Healthcare Fund LP","title":"","shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"RA Capital Nexus Fund II, L.P.","title":"","shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Kolchinsky Peter","title":"","shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Shah Rajeev M.","title":"","shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"BAUM CHARLES M","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"TOMSICEK MICHAEL JOHN","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Shacham Sharon","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Mirza Mansoor Raza","title":"Chief Medical Officer","shares":38817,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Blume-Jensen Peter","title":"President and CEO","shares":180095,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Masson Kristina","title":"EVP - Business Operations","shares":180095,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Blume-Jensen Peter","title":"President and CEO","shares":72706,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Masson Kristina","title":"EVP - Business Operations","shares":72706,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Devroe Eric","title":"Chief Operating Officer","shares":72981,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Levy Adam D.","title":"Chief Financial Officer","shares":46167,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Gamelin Erick","title":"Chief Development Officer","shares":38584,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Miller Mary","title":"Chief Legal Officer","shares":49830,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Peterson Katharine","title":"Chief Accounting Officer","shares":14227,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"DiRocco Derek","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.a","reporter":"Palani Santhosh","title":null,"shares":9366,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Blume-Jensen Peter","title":"President and CEO","shares":1253,"price_per_share":1.92,"usd_value":2406,"security_title":"Common Stock","importance":15.00240576},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Masson Kristina","title":"EVP - Business Operations","shares":1253,"price_per_share":1.92,"usd_value":2406,"security_title":"Common Stock","importance":15.00240576},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Devroe Eric","title":"Chief Operating Officer","shares":613,"price_per_share":1.92,"usd_value":1177,"security_title":"Common Stock","importance":15.00117696},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Blume-Jensen Peter","title":"President and CEO","shares":490,"price_per_share":1.92,"usd_value":941,"security_title":"Common Stock","importance":15.0009408},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Masson Kristina","title":"EVP - Business Operations","shares":490,"price_per_share":1.92,"usd_value":941,"security_title":"Common Stock","importance":15.0009408},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Gamelin Erick","title":"Chief Development Officer","shares":404,"price_per_share":1.92,"usd_value":776,"security_title":"Common Stock","importance":15.00077568},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Miller Mary","title":"Chief Legal Officer","shares":184,"price_per_share":1.92,"usd_value":353,"security_title":"Common Stock","importance":15.00035328},{"ts":"2026-05-14","kind":"sec.insider.f","reporter":"Peterson Katharine","title":"Chief Accounting Officer","shares":99,"price_per_share":1.92,"usd_value":190,"security_title":"Common Stock","importance":15.00019008},{"ts":"2026-05-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Acrivon Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001781174/10-q/0001193125-26-221634","accession_number":"0001193125-26-221634","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Acrivon Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001781174/8-k/0001193125-26-221626","accession_number":"0001193125-26-221626","importance":35}]}